Clinical Psychopharmacology Prakash B

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Psychopharmacology Prakash B Clinical Psychopharmacology Prakash B. Behere • Anweshak Das Aniruddh P. Behere Clinical Psychopharmacology An Update Prakash B. Behere Anweshak Das Department of Psychiatry Consultant Psychiatrist D Y Patil Medical College & D. Y. Patil Psychiatric Clinic Education Society (Deemed University) Guwahati Kolhapur Assam Maharashtra India India Aniruddh P. Behere Pediatric Behavior Health Helen Devos Childrens’s Hospital Michigan State University College of Human Medicine Grand Rapids, Michigan USA ISBN 978-981-13-2091-0 ISBN 978-981-13-2092-7 (eBook) https://doi.org/10.1007/978-981-13-2092-7 Library of Congress Control Number: 2018957629 © Springer Nature Singapore Pte Ltd. 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore Dedicated to My Wife Mrs. Manikyamba Prakash Behere This book is the outcome of her inspiration. —Prakash B. Behere Foreword It is a pleasure to write the foreword for Dr. Prakash Behere’s latest book entitled Clinical Psychopharmacology: An Update. Dr. Behere was my postgraduate stu- dent at the Postgraduate Institute of Medical Education and Research, Chandigarh, during my early days as a postgraduate teacher. We have had interaction several times since. I regard him as a very talented individual whose work in the area of mental health, especially in the use of medications to treat different forms of mental disorders has been exceptional and has vast clinical experience in treating the men- tally ill. He has vast clinical experience in treating the mentally ill. The purpose of this book is to highlight what the specific medicines offer in terms of benefits, side effects, and risks. It provides practical information on how to use various psychotro- pic drugs in clinical practice, emphasizing the mechanisms of action of these drugs upon the receptors and enzymes in the brain. Prof. Behere has worked to ensure that all the information in this book concern- ing drug dosages, schedules, routes of administration, indications and contraindica- tions, etc., is accurate at the time of publication. The book consists of 11 chapters in all and the 10th chapter covers special populations which include the elderly, chil- dren, adolescents, nursing and pregnant women. Prof. Behere presents a balanced and an even approach in his writing which allows the reader to consider the current range of views about modern psychotropic medications. The publication of this book is a major event in the field of psycho- pharmacology and represents a unique contribution to all mental health profession- als. It has 11 chapters and interestingly at the end of every chapter there is a block covering summary of that chapter. I believe it is a book every medical practitioner would benefit from having access to and will add to the treasure of existing books in psychopharmacology. Finally, I am happy to write the Foreword for this book. Naren N. Wig Postgraduate Institute of Medical Education and Research Chandigarh, India vii Preface This is an effort to provide an up-to-date, easy to use, and a portable source of drug information for mental health professionals. This guide is intended to complement Essential Psychopharmacology and Textbook of Psychopharmacology. It provides practical information on how to use various psychotropic drugs in clinical practice, emphasizing the mechanisms of action of these drugs upon the receptors and enzymes in the brain. Earlier we have written a book entitled Handbook of Clinical Psychopharmacology in 2010, which was our initial attempt to write in psychopharmacology. As this earlier book became very popular among postgraduates in psychiatry, we penned this book. It consists of 11 chapters—10 chapters cover various classes of drugs, and the 10th chapter covers special populations which include the elderly, children, adoles- cents, pregnant and nursing women. All the selected drugs are presented in the same design format in order to facilitate rapid access to information. Specifically, each drug is individually divided into sections—class of the drug, history and introduc- tion, classification, pharmacological action, doses, drug interactions, indications, side effects, and special population. Only the essential facts about each drug have been included in order to make the content concise and to avoid dilution of impor- tant information. At the end of chapters, there is a block giving summary of the chapter. This book is intended to be genuinely helpful for practitioners of psychopharma- cology by providing them with facts and relevant details of all the important psy- chotropic drugs. Every effort has been made to provide accurate and up-to-date information in accordance with the accepted standards and practice at the time of publication. Kolhapur, India Prakash B. Behere Guwahati, India Anweshak Das Grand Rapids, MI Aniruddh P. Behere ix Contents 1 Antidepressants ������������������������������������������������������������������������������������������ 1 1.1 Tricyclic and Tetracyclic Antidepressants ������������������������������������������ 1 1.2 Specific Serotonin Reuptake Inhibitors ���������������������������������������������� 4 1.2.1 Fluoxetine ������������������������������������������������������������������������������ 4 1.2.2 Sertraline �������������������������������������������������������������������������������� 7 1.2.3 Fluvoxamine �������������������������������������������������������������������������� 9 1.2.4 Paroxetine and Paroxetine CR ������������������������������������������������ 11 1.2.5 Citalopram and Escitalopram �������������������������������������������������� 13 1.3 Monoamine Oxidase Inhibitors ���������������������������������������������������������� 15 1.4 Selective Serotonin Norepinephrine Reuptake Inhibitors ������������������ 18 1.4.1 Venlafaxine and Desvenlafaxine �������������������������������������������� 18 1.4.2 Duloxetine ������������������������������������������������������������������������������ 20 1.4.3 Milnacipran ���������������������������������������������������������������������������� 22 1.5 Norepinephrine Dopamine Reuptake Inhibitors �������������������������������� 23 1.5.1 Bupropion ������������������������������������������������������������������������������ 23 1.6 Serotonin Adrenaline Reuptake Inhibitors ������������������������������������������ 25 1.6.1 Trazodone ������������������������������������������������������������������������������� 25 1.6.2 Nefazodone ���������������������������������������������������������������������������� 27 1.7 Noradrenaline and Specific Serotonergic Agents ������������������������������� 28 1.7.1 Mirtazapine ���������������������������������������������������������������������������� 28 1.8 Newer Antidepressants ������������������������������������������������������������������������ 30 1.8.1 Agomelatine ���������������������������������������������������������������������������� 30 1.8.2 Opipramol ������������������������������������������������������������������������������ 32 1.8.3 Dapoxetine ������������������������������������������������������������������������������ 33 1.8.4 Vilazodone ������������������������������������������������������������������������������ 35 1.9 Important Tables Related to Antidepressants �������������������������������������� 36 1.10 Points to Remember ���������������������������������������������������������������������������� 38 2 Antipsychotics �������������������������������������������������������������������������������������������� 39 2.1 Typical Antipsychotics ������������������������������������������������������������������������ 39 2.1.1 Chlorpromazine ���������������������������������������������������������������������� 42 2.1.2 Haloperidol ���������������������������������������������������������������������������� 43 2.1.3 Sulpiride and Levosulpiride ���������������������������������������������������� 44 2.1.4 Loxapine �������������������������������������������������������������������������������� 46 xi xii Contents 2.2 Atypical Antipsychotics ���������������������������������������������������������������������� 48 2.2.1 Olanzapine ������������������������������������������������������������������������������
Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • ZHONG-THESIS-2016.Pdf
    ANTIDEPRESSANTMINING AZ AMAZ DESIGNING A WEBBASED ALGORITHM AND VISUAL LANGUAGE FOR ANTIDEPRESSANT DRUG SELECTION TO EDUCATE PRIMARY CARE PRACTITIONERS By Amy Zhong A thesis submitted to Johns Hopkins University in conformity with the requirements for the degree of Master of Arts Baltimore, Maryland March, 2016 © 2016 Amy Zhong All Rights Reserved ABSTRACT Depression is a common mental disorder that affects approximately 14.8 million American adults each year. In addition to being a debilitating condition, depression often occurs in tandem with other medical conditions such as diabetes, heart disease, and cancer. While psychiatric professionals are essential for the management of mental health, majority of patients seek care from their primary care practitioners. This phenomenon is of great concern because diagnosis of depression within primary care settings has only been accurate 25-50% of the time. The antidepressant drug selection algorithm utilizes a unique formula to integrate patient and family medical histories, patient symptoms, and patient preferences to make optimal treatment selections. The development of a visual language explores the use of graphic elements to improve understanding of major pharmacological mechanisms, knowledge essential to making rational DQWLGHSUHVVDQWGUXJVHOHFWLRQV,QFUHDWLQJWKLVPRELOHZHEEDVHGDSSOLFDWLRQZHKRSHWR¿OOD void in resources available to primary care practitioners, and improve management of mental health within the primary care setting. By Amy Zhong Chairpersons of the Supervisory Committee Adam I. Kaplin, M.D., Ph.D., esis Preceptor Assistant Professor, Departments of Psychiatry and Neurology e Johns Hopkins University School of Medicine Kristen Rahn Hollinger, Ph.D., esis Preceptor Instructor, Departments of Psychiatry and Neurology e Johns Hopkins University School of Medicine Jennifer E.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Flibanserin (Addyi)
    STEPS New Drug Reviews Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder in Premenopausal Women HARRY HOLT, MD, and JEFFREY TINGEN, PharmD, MBA, University of Virginia Health System, Charlottesville, Virginia STEPS new drug reviews Flibanserin (Addyi) is labeled for the treatment of acquired, generalized hypoactive sexual cover Safety, Tolerability, desire disorder (HSDD) in premenopausal women. It is a nonhormonal medication that Effectiveness, Price, and 1 Simplicity. Each indepen- affects serotonin receptors to increase libido. dent review is provided by authors who have no financial association with Drug Dosage Dose form Cost* the drug manufacturer. Flibanserin (Addyi) 100 mg per day at bedtime 100-mg tablet $830 This series is coordinated by Allen F. Shaughnessy, *—Estimated retail price of one month’s treatment based on information obtained at http://www.goodrx.com PharmD, MMedEd, (accessed April 1, 2016). Contributing Editor. A collection of STEPS pub- lished in AFP is available at http://www.aafp.org/ SAFETY EFFECTIVENESS afp/steps. The main risks of flibanserin are hypoten- Flibanserin has been evaluated in three ran- sion (2%) and syncope (0.4%), which are domized, double-blind, placebo-controlled more likely to occur in patients who have studies of 2,375 premenopausal women also ingested alcohol. For this reason, women with acquired, generalized HSDD, defined should not drink alcohol when taking fliban- as low sexual desire causing marked dis- serin; about one in six persons taking this tress or interpersonal difficulties.2 Women combination will experience clinically signif- in monogamous, heterosexual relationships icant hypotension and syncope.1 Flibanserin with no known cause of HSDD reported should not be taken by women with hepatic an average increase of 1.6 to 2.5 additional impairment or women who are also taking satisfying sexual events per month with treat- moderate or strong cytochrome P450 3A4 ment, from a baseline of 2.5 to 3.0 per month.
    [Show full text]
  • MODERN INDICATIONS for the USE of OPIPRAMOL Krzysztof Krysta1, Sławomir Murawiec2, Anna Warchala1, Karolina Zawada3, Wiesław J
    Psychiatria Danubina, 2015; Vol. 27, Suppl. 1, pp 435–437 Conference paper © Medicinska naklada - Zagreb, Croatia MODERN INDICATIONS FOR THE USE OF OPIPRAMOL Krzysztof Krysta1, Sławomir Murawiec2, Anna Warchala1, Karolina Zawada3, Wiesław J. Cubała4, Mariusz S. Wiglusz4, Katarzyna Jakuszkowiak-Wojten4, Marek Krzystanek5 & Irena Krupka-Matuszczyk1 1Department of Psychiatry and Psychotherapy, Medical University of Silesia, Katowice, Poland 2“Dialogue” Therapy Centre, Warsaw, Poland 3Department of Pneumonology, Medical University of Silesia, Katowice, Poland 4Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland 5Department of Rehabilitation Psychiatry, Medical University of Silesia, Katowice, Poland SUMMARY Opipramol is considered as a pharmacological agent that does not fit the classification taking into account the division of antidepressants, antipsychotics and anxiolytics. It has a structure related to tricyclic antidepressants but it has a different mechanism of action, i.e. binding to sigma1 and to sigma2 sites. It has been regarded as an effective drug in general anxiety disorders together with other agents like SSRI`s, SNRI`s, buspirone and pregabalin for many years. It can however also be indicated in other conditions, e.g. it may be used as a premedication in the evening prior to surgery, positive results are also observed in psychopharmacological treatment with opipramol in somatoform disorders, symptoms of depression can be significantly reduced in the climacteric syndrome. The latest data from literature present also certain dangers and side effects, which may result due to opipramol administration. Mania may be induced not only in bipolar patients treated with opipramol, but it can be an adverse drug reaction in generalized anxiety disorder. This analysis shows however that opipramol is an important drug still very useful in different clinical conditions.
    [Show full text]
  • Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia
    Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia THE TREATMENT OF THE SCHIZOPHRENIA: AN OVERVIEW Gabriella Galizia School of Pharmacy,University of Salerno, Italy e-mail: [email protected] Summary The schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person. The terms antipsychotic and neuroleptic define a group of medicine principally used to treat schizophrenia, but they are also efficacious for other psychosis and in states of psychic agitation. The antipsychotics are divided into two classes: classic or typical and atypical. The paliperidone, the major metabolite of risperidone, shares with the native drug the characteristics of receptoral bond and of antagonism of serotonin (5HT2A) and dopamine (D2). It's available in a prolonged release formulation and it allows the administration once daily. Besides, the paliperidone has a pharmacological action independent of CYT P450 and in such way a lot of due pharmacological interactions would be avoided to interference with the activity of the CYP2D6, that is known to have involved in the metabolism of the 25% of the drugs of commune therapeutic employment. Introduction The schizophrenia has been a very hard disease to investigate by the research. This is not surprising because it involves the most mysterious aspects of human mind, as emotions and cognitive processes. According to scientific conventions, the schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person.
    [Show full text]
  • Opipramol and Trifluoperazine in the Treatment of Anxiety and Tension
    A COMPARATIVE STUDY OF TWO ANTIHISTAMINES 395 In table VI are given the results of a question directed at discovering how effective the preferred treatment was compared to any other antihistamine used. Fifteen patients only were able to give this information but the results are interesting. Discussion TABLE VI The design of this study was very simple as COMPARISON WITH PREVIOUSLY USED ANTIHISTAMINE such studies must be if they are to be completed under the conditions of a busy general practice. In a condition such as hay fever where anti- Worse As good Better Total histamines are known to be etfective and where fairly rapid symptomatic relief is needed by the 2 4 9 15* patient, we did not feel justified in including a placebo. The results of the study seem fairly *In the majority of patients the previously used clear-cut that if patients are offered the choice antihistamine was the chemically related chlor- of a plain form of this antihistamine or a long- pheniramine maleate B.P. acting form more will choose the latter. Ofthose that do so, however, only about a third find a single tablet at night completely effective, the remainder have to take one further tablet during the day. Both forms of antihistamine are effective and where a retrospective comparison can be made this effectiveness is considered greater or equal to that of previously administered anti-histamines. Summary A simple comparative study under general-practice conditions of two formulations of pheniramine is described. Sixty-one per cent of patients preferred the long-acting form of this antihistamine.
    [Show full text]
  • Dosing and Monitoring: Children and Adolescents
    Dosing and Monitoring: Children and Adolescents Glenn S. Hirsch, MD Keith S. Ditkowski, MD Child & Adolescent Dosing.indd 1 08-01-2018 14:56:52 Adapted from Child & Adolescent Dosing.indd 76 08-01-2018 14:56:50 DISCLAIMER This pocket reference is provided as a service to medicine by the publisher, Medworks Media Inc. This review does not imply the publisher’s agreement with the views expressed herein. Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation. In an effort to allow for the widest distribution of these guidelines, the authors have modified the originally printed material to more closely conform to the limitations of product labeling. For many of the drugs discussed herein, initiation at lower doses may increase tolerability and efficacy. Copyright ©2018, MedWorks Media Inc., 2205 Rockefeller Lane, Redondo Beach, CA 90278. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form. Child & Adolescent Dosing.indd 2 08-01-2018 14:56:52 Dosing and Monitoring: Children and Adolescents Glenn S. Hirsch, MD Keith S. Ditkowski, MD Dr. Hirsch is the deputy director of the New York University Child Study Center, the medical director in the Division of Child and Adolescent Psychiatry, and the assistant professor of psychiatry at the New York University School of Medicine.
    [Show full text]
  • Determination of Antidepressants in Human Plasma by Modified Cloud
    pharmaceuticals Article Determination of Antidepressants in Human Plasma by Modified Cloud-Point Extraction Coupled with Mass Spectrometry El˙zbietaGniazdowska 1,2 , Natalia Korytowska 3 , Grzegorz Kłudka 3 and Joanna Giebułtowicz 3,* 1 Łukasiewicz Research Network, Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland; [email protected] 2 Department of Bioanalysis and Drugs Analysis, Doctoral School, Medical University of Warsaw, 61 Zwirki˙ i Wigury, 02-091 Warsaw, Poland 3 Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland; [email protected] (N.K.); [email protected] (G.K.) * Correspondence: [email protected] Received: 5 October 2020; Accepted: 7 December 2020; Published: 12 December 2020 Abstract: Cloud-point extraction (CPE) is rarely combined with liquid chromatography coupled to mass spectrometry (LC–MS) in drug determination due to the matrix effect (ME). However, we have recently shown that ME is not a limiting factor in CPE. Low extraction efficiency may be improved by salt addition, but none of the salts used in CPE are suitable for LC–MS. It is the first time that the influences of a volatile salt—ammonium acetate (AA)—on the CPE extraction efficiency and ME have been studied. Our modification of CPE included also the use of ethanol instead of acetonitrile to reduce the sample viscosity and make the method more environmentally friendly. We developed and validated CPE–LC–MS for the simultaneous determination of 21 antidepressants in plasma that can be useful for clinical and forensic toxicology. The selected parameters included Triton X-114 concentration (1.5 and 6%, w/v), concentration of AA (0, 10, 20 and 30%, w/v), and pH (3.5, 6.8 and 10.2).
    [Show full text]
  • (Flibanserin) (Flibanserin) Tablets
    ™ MEDICATION GUIDE addyi ADDYI™ (add-ee) (flibanserin) (flibanserin) Tablets Read this Medication Guide before you start taking ADDYI™ and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor. What is the most important information I should know about ADDYI? Your risk of severe low blood pressure and fainting (loss of consciousness) is increased if you take ADDYI and: • drink alcohol. Do not drink alcohol if you take ADDYI. • take certain prescription medicines, over-the-counter medicines, or herbal supplements. Do not take or start taking any prescription medicines, over-the-counter medicines, or herbal supplements while taking ADDYI until you have talked with your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI. • have liver problems. Do not take ADDYI if you have liver problems. If you take ADDYI and you feel lightheaded or dizzy, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you faint (lose consciousness). If you faint (lose consciousness), tell your doctor as soon as you can. ADDYI is only available through the ADDYI Risk Evaluation and Mitigation Strategy (REMS) Program because of the increased risk of severe low blood pressure and fainting (loss of consciousness) with alcohol use. You can only get ADDYI from pharmacies that are enrolled in the ADDYI REMS Program. For more information about the Program and a list of pharmacies that are enrolled in the ADDYI REMS Program, go to www.AddyiREMS.com or call 1-844-PINK-PILL (1-844- 746-5745).
    [Show full text]